acylfulvene and Lymphoma--Non-Hodgkin

acylfulvene has been researched along with Lymphoma--Non-Hodgkin* in 1 studies

Other Studies

1 other study(ies) available for acylfulvene and Lymphoma--Non-Hodgkin

Article	Year
LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair. Oncotarget, 2023, 06-12, Volume: 14 Despite advances in therapies treating non-Hodgkin's lymphoma (NHL), 20~40% of patients experience relapsed or refractory disease. While solid tumors with homologous recombination deficiencies have been successfully targeted with synthetic lethal agents such as poly-ADP ribose polymerase (PARP) inhibitors, such synthetic lethality strategy has not yet been approved to treat patients with NHL. Here we investigated the mechanism of action (MoA) and therapeutic potential of a new-generation acylfulvene compound, LP-284, in both Topics: Animals; Bortezomib; DNA Breaks, Double-Stranded; DNA Repair; Humans; Lymphoma, Non-Hodgkin; Mice	2023

Article

Year

LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.

Oncotarget, 2023, 06-12, Volume: 14

Despite advances in therapies treating non-Hodgkin's lymphoma (NHL), 20~40% of patients experience relapsed or refractory disease. While solid tumors with homologous recombination deficiencies have been successfully targeted with synthetic lethal agents such as poly-ADP ribose polymerase (PARP) inhibitors, such synthetic lethality strategy has not yet been approved to treat patients with NHL. Here we investigated the mechanism of action (MoA) and therapeutic potential of a new-generation acylfulvene compound, LP-284, in both

Topics: Animals; Bortezomib; DNA Breaks, Double-Stranded; DNA Repair; Humans; Lymphoma, Non-Hodgkin; Mice

2023